Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer staging system put to the test in chinese patients

NCT ID NCT07088861

Knowledge-focused Sponsor: Lirong Wu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether the newest version of the cancer staging system (TNM-9) accurately predicts outcomes for people with nasopharyngeal carcinoma in parts of China where the disease is less common. Researchers will review medical records from about 1,400 patients treated between 2011 and 2023. The goal is to see if the new system helps doctors better plan treatment and understand patient prognosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,401 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2011

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged 18 to 75 years, any sex, newly diagnosed with histologically confirmed nasopharyngeal carcinoma (NPC) from non-high-incidence areas in China (Jiangsu, Zhejiang, Anhui). All patients were treatment-naïve, completed high-quality MRI of the nasopharynx and neck, and received standard radiotherapy-based treatment. Eligible patients had adequate organ function, ECOG 0-1, Karnofsky score ≥70, and expected survival \>3 months. Exclusion criteria included prior treatment (radiotherapy, chemotherapy, or surgery), severe comorbidities, uncontrolled infections, active autoimmune diseases needing immunosuppression, pregnancy or lactation, and incomplete or non-standard radiotherapy data.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-75 years old and gender * Long-term residence in a non-high prevalence area for nasopharyngeal cancer * Histologically confirmed primary nasopharyngeal cancer (without any treatment) * Completed MRI examination of nasopharynx and neck with image quality meeting the needs of imaging analysis * All receiving a standard comprehensive treatment plan with radiotherapy as the core * Adequate bone marrow, liver, and kidney function (meeting laboratory index thresholds) * ECOG 0-1, KPS ≥ 70 points, and life expectancy \> 3 months * No previous history of immune disorders Exclusion Criteria: * Received radiotherapy, chemotherapy, or surgery to the primary site or lymph nodes * Severe underlying disease (heart failure, renal failure, etc.), uncontrolled active infection, active autoimmune disease, or history of autoimmune disease requiring immunosuppressive therapy * Pregnant or breastfeeding females * Irregular radiotherapy or missing treatment data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nasopharyngeal carcinoma (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nasopharyngeal carcinoma (NPC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.